Kooli A, Graham C, Scheuer N, Gilloteau I, Miles L, Sherif B, McBride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared to ustekinumab and etanercept in Morocco. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Kooli A, Graham C, Scheuer N, Gilloteau I, Miles L, Sherif B, McBride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared to ustekinumab and etanercept in Tunisia. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Warren R, Halliday A, Graham CN, Gilloteau I, Miles L, Sherif B, McBride D. Secukinumab significantly reduces work impairment and indirect costs compared to ustekinumab and etanercept in the United Kingdom. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland.
Odom DM, Mladsi DM, Saag KG, Sherif BN, Miles L, Ronquest N, Wang J. Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literature reviews. Clin Ther. 2014 Jun;36(6):906-17. doi: 10.1016/j.clinthera.2014.04.012.